Moving cannabis to a category of drugs that includes some common medicines will have implications for research, businesses and patients.

Moving cannabis to a category of drugs that includes some common medicines will have implications for research, businesses and patients.

The agency’s high-level turnover and conflicting policy decisions on drug oversight have fueled concerns about the leadership of Dr. Marty Makary.Dr. Marty Makary, the F.D.A. commissioner, has faced intense criticism as the agency undergoes top-level turnover in critical areas like drug approvals.

Proposed new rules would pull all federal financing from hospitals that continue to provide gender treatments for adolescents.Health Secretary Robert F. Kennedy Jr., with President Trump and Mehmet Oz, the Medicaid and Medicare services administrator, in the White House in September.

Familial feuds have ripple effects, experts say.